Smartest Doc
Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer
European Journal of Cancer, 05/24/2012
Clinical Article
van Baardwijk A et al. – Individualised accelerated radiotherapy (INDAR) in concurrent chemo–radiation based on normal tissue constraints is feasible, even in patients with large tumour volumes and multi–level N2–3 disease, with acceptable severe late toxicity and promising 2–year survival.